:::

Content

:::

Diagnostic Molecular Markers for Endometrial Cancer

Period:106/12/01-108/5/31

Back

Taipei Medical University Hospital.

Principal Investigator:賴鴻政

Project Manager:朱俐人

 

 

 

About the Team

 

Developing a non-invasive in-vitro endometrial cancer kit, including BHLHE22 methylation, with high sensitivity and specificity for endometrial cancer diagnosis.

 

 

Development

Completed product specification standards, carried out clinical test in three medical centers, and devised a business plan,On August 7, 2018 formedGuzip Biomarkers Corporation .